Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Cue Biopharma, Inc. develops precision immunotherapies targeting T cells to treat cancer and autoimmune diseases. Its proprietary Immuno-STAT platform selectively modulates disease-relevant T cells, aiming to restore immune balance. The company’s core programs include autoimmune, autoimmune cell depletion, and oncology candidates, with a focus on personalized, targeted biologics designed to improve efficacy and safety over traditional therapies.
This description was generated via AI from an annual report. Updated about 1 year ago.